Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592264 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A Phase 1 study, sponsored by OBI Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03592264 is a Phase 1 study that was terminated before completion, run by OBI Pharma. The registered enrollment target is 68 participants.
The verdict
NCT03592264, a Phase 1 study, was terminated before completion, sponsored by OBI Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
Interventions
- DRUG OBI-3424
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592264
The ClinicalTrials.gov registry entry for NCT03592264 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OBI Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OBI-3424 is the first listed.
NCT03592264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03592264 about?
NCT03592264 is a clinical study titled "A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors". A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
What is the current status of trial NCT03592264?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-07-02. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT03592264?
The interventions under investigation include: OBI-3424 (DRUG).
Who is sponsoring clinical trial NCT03592264?
This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.